MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Effects of Food on the Bioavailability and Pharmacokinetic Profile of Itasetron After a Single Oral Dose in Healthy Male Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Itasetron tablet
Drug: Itasetron infusion
Other: high fat breakfast
First Posted Date
2014-10-09
Last Posted Date
2014-10-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
15
Registration Number
NCT02259985

Study to Investigate Safety and Tolerability of BI 1744 CL in Free Dose Combination With Tiotropium Bromide Both Administered by Respimat® in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
Drug: BI 1744 CL
Drug: Tiotropium bromide
First Posted Date
2014-10-09
Last Posted Date
2014-10-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
48
Registration Number
NCT02259946

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of KUC 7483 CL Tablets in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: KUC 7483 CL - single rising dose
Drug: Placebo
Other: standardized high fat meal
First Posted Date
2014-10-09
Last Posted Date
2014-10-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
24
Registration Number
NCT02259764

Dose Tolerance Study in Healthy Male Volunteers After Intranasal Application of Epinastine Nasal

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Epinastine nasal
Drug: Placebo
First Posted Date
2014-10-09
Last Posted Date
2014-10-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
39
Registration Number
NCT02260037

Bioavailability of Telmisartan/Amlodipine Fixed Dose Combination in Healthy Male and Female Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Telmisartan/Amlodipine
Other: high fat, high caloric meal
First Posted Date
2014-10-09
Last Posted Date
2014-10-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
40
Registration Number
NCT02259777

In Vitro/in Vivo Correlation (IVIVC) for Oral Slow Release (SR) Tablets Pramipexole in Healthy Male Volunteers

First Posted Date
2014-10-09
Last Posted Date
2014-10-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
15
Registration Number
NCT02260024

Study of the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to the Market Standard, Atrovent® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease

Phase 2
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: Atrovent® CFC inhalation aerosol
Drug: Ipratropium bromide HFA-134a inhalation aerosol
Drug: Placebo
First Posted Date
2014-10-09
Last Posted Date
2014-10-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
41
Registration Number
NCT02260011

Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment

Phase 1
Completed
Conditions
Hepatic Insufficiency
Interventions
Drug: Tipranavir
Drug: Ritonavir
Drug: Pegylated interferon
Drug: Ribavirin
First Posted Date
2014-10-09
Last Posted Date
2014-10-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
36
Registration Number
NCT02259855

Safety, Tolerability and Pharmacokinetics of KUC 7483 Tablets in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
Drug: KUC 7483 CL
Other: High fat meal
First Posted Date
2014-10-09
Last Posted Date
2014-10-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
50
Registration Number
NCT02259907

Study of New Tablet Formulations and Suspension Formulation Compared to Current (1B) Formulation of BILR 355 BS in Healthy Male Volunteer Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BILR 355 BS /1B, current low dose formulation
Drug: BILR 355 BS /1B, current high dose formulation
Drug: BILR 355 BS - Jet Milled (JM) + Sodium Dodecyl Sulfate (SDS) formulation
Drug: BILR 355 BS - Suspension low dose
Drug: Ritonavir
Drug: BILR 355 BS - Hammer Milled (HM) + Sodium Dodecyl Sulfate (SDS) formulation
Drug: BILR 355 BS - Suspension high dose
First Posted Date
2014-10-09
Last Posted Date
2018-08-31
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
88
Registration Number
NCT02259868
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy